Xilio Therapeutics (XLO) Other Non-Current Assets (2020 - 2026)

Xilio Therapeutics has disclosed Other Non-Current Assets across 7 years of filings, most recently posting $1.8 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.8 million, up 1.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 1.4% YoY), and the FY2025 annual result was $1.8 million, up 1.4% from the prior year.
• Other Non-Current Assets came in at $1.8 million for Q1 2026 at Xilio Therapeutics, roughly flat from $1.8 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q1 2026 to a low of $121000.0 in Q1 2024.
• The 5-year median for Other Non-Current Assets is $1.6 million (2023), against an average of $1.4 million.
• Across the five-year window, Other Non-Current Assets plunged 85.06% in 2023 and jumped 1377.69% in 2025, its largest moves.
• Xilio Therapeutics' Other Non-Current Assets stood at $267000.0 in 2022, then soared by 494.38% to $1.6 million in 2023, then gained by 12.29% to $1.8 million in 2024, then advanced by 1.4% to $1.8 million in 2025, then grew by 0.33% to $1.8 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.